cro.directory
← Home
ProPharma Group logo

ProPharma Group

Regulatory, pharmacovigilance, medical information, and clinical services for life sciences companies

ProPharma Group provides pharmacovigilance, regulatory sciences, medical information, medical writing, and biostatistics services to life sciences companies. Its regulatory offering covers FDA and European work, including an AI-assisted capability for ANDA submission development.

Services

About this organization

Overview

ProPharma Group provides outsourced services to life sciences clients, including regulatory sciences, pharmacovigilance, medical information, clinical research, and quality and compliance.

Service areas named in the site navigation

  • Regulatory sciences: FDA regulatory consulting, FDA meeting support, European regulatory development, European marketing authorization holder partnering, lifecycle management, regulatory operations, advertising and promotional review, market access and reimbursement strategy, nonclinical development, and medical device solutions.
  • CRO services: full-service CRO, site and patient services, global medical writing and transparency, biostatistics and programming, medical device, and clinical operations.
  • Pharmacovigilance: clinical and post-marketing pharmacovigilance, safety systems, QPPV and LPPV, case management, global literature review, signal management, periodic safety reports and risk management plans, and global ICSR submissions.
  • Medical information: global contact center support, adverse event and product complaint intake and follow-up.
  • Quality and compliance: computer system validation, GxP compliance and auditing, inspection readiness, commissioning, qualification and validation, clinical quality assurance, and cell and gene therapy consulting.

Recent activity

  • Unveiled an AI-assisted capability to support ANDA submission development (July 2026).
  • Added a Vice President of HEOR and Market Access to strengthen integrated EU regulatory, HTA, reimbursement, and market access capabilities (June 2026).
  • Published an SBTi-validated net-zero greenhouse gas reduction target aligned with the Net-Zero Standard, with a commitment to reach net-zero by 2050 (January 2026).

Recognition

  • Silver at ECCCSA for AI innovation in medical information (January 2025).
  • 2024 CPHI Pharma Award for regulatory and compliance innovation (October 2024).
  • 2024 Clinical Trials Excellence Award (September 2024).

Similar profiles by shared services, phases, and indications.

View all alternatives →See similar CROs ranked by shared capabilities

Submit a verified review for this organization.

Markdown mirror: /companies/propharmagroup.md